Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Celgene Gains Hematology And Oncology Muscle With Pharmion Acquisition

  • News

Executive Summary

Celgene sees its acquisition of Pharmion as a move to improve its position in the hematology and oncology markets

You may also be interested in...



Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation

U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.

Celgene Ups Vidaza Discount To Gain Positive NICE Recommendation

U.K. cost-watchdog NICE recommends reimbursement for Celgene's Vidaza after the company offers a steeper discount.

Celgene’s Revlimid Gains Blockbuster Status; Vidaza Poised To Gobble MDS Market Share

NICE posts positive recommendation for Vidaza payment in England, Wales.

Table

View full table

Tags:
Latest Headlines

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

Changes To EU Pharma Reform: More Questions Than Answers?

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

See All
UsernamePublicRestriction

Register

PS049039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By